Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504556 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,146
- Enrollment target
NCT00504556: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00504556 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,146 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (762% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504556, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,146 participants
- Enrollment target
Study Summary
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
Primary Outcome
Adjudicated Incidence of Bleeding Events during treatment period
Interventions
- DRUG warfarin
- DRUG Edoxaban (DU-176b)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,146 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
What the finished NCT00504556 record still lists
NCT00504556 is an interventional study that assigns participants to a tested intervention. Its 1,146 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (762% higher).
The record links to 0 conditions, and to 2 interventions - of which warfarin is the first listed.
NCT00504556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00504556 about?
NCT00504556 is a clinical study titled "A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation". This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
What is the current status of trial NCT00504556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,146 participants. The study started on 2007-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00504556?
The interventions under investigation include: warfarin (DRUG), Edoxaban (DU-176b) (DRUG).
Who is sponsoring clinical trial NCT00504556?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00504556's enrollment target sits among peer trials
1,146 20th of 2000 higher than 1,981 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia